SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-21-000226
Filing Date
2021-11-17
Accepted
2021-11-17 17:15:54
Documents
12
Period of Report
2021-11-17
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20211117.htm   iXBRL 8-K 38125
  Complete submission text file 0001725160-21-000226.txt   181955

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20211117.xsd EX-101.SCH 1902
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20211117_lab.xml EX-101.LAB 25848
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20211117_pre.xml EX-101.PRE 13581
5 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20211117_htm.xml XML 11756
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 211421504
SIC: 2834 Pharmaceutical Preparations